Snapshot from Aug 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / p-tau217 blood test predicts Alzheimer's risk
Tech medical research

p-tau217 blood test predicts Alzheimer's risk

Analysis based on 56 articles · First reported Jul 15, 2026 · Last updated Aug 04, 2026

Sentiment
20
Attention
4
Articles
56
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The findings could accelerate development of Alzheimer's treatments by enabling better patient selection for clinical trials. Diagnostic companies and biotech firms focused on Alzheimer's biomarkers may see increased interest, though near-term market impact is limited as the test is not yet recommended for healthy individuals.

Healthcare Biotechnology Diagnostics
Event Summary

A study published in JAMA and presented at the Alzheimer s Association in London found that a blood test measuring p-tau217 levels can predict the risk of developing Alzheimer's symptoms in cognitively healthy older adults over the next 5 to 10 years. The research, led by Mass General Brigham, analyzed data from 2,684 participants across six cohorts in North America, Japan, and Australia. Those with very high p-tau217 levels had a 38% risk of cognitive impairment within 5 years and up to 78% within 10 years. Experts caution that the test is not yet ready for widespread use in asymptomatic individuals, but it could aid in clinical trial enrollment and future preventive treatments.

Key Actions
60 Alzheimer s Association presented findings
50 United States — Food and Drug Administration cleared test Fujirebio
50 Reisa Sperling advised against testing
35 Suzanne E. Schindler commented on study
32 United States — National Institutes of Health provided funding
30 David Wolk commented on study
30 Eli Lilly and Company funded research
20 Jessica Langbaum discouraged testing
20 Richard A. Isaacson cautioned against single test
20 United States — United States Department of Defense funded research
15 Laura Nisenbaum stated blood tests not diagnosis
Entities Involved
per
Reisa Sperling
Senior author; emphasized the test's potential and cautioned against premature use.
Importance 80.0 Sentiment 20.0
per
Rachel F. Buckley
Lead author; highlighted the test's ability to estimate individual risk.
Importance 70.0 Sentiment 20.0
ngo
Alzheimer s Association
Venue for presenting the research; highlights conference's role in disseminating Alzheimer's research.
Importance 50.0 Sentiment 10.0
per
Suzanne E. Schindler
Co-authored commentary noting limitations; studies p-tau217's prognostic potential.
Importance 40.0 Sentiment 0.0
per
David Wolk
Co-authored commentary noting limitations; from University of Pennsylvania.
Importance 40.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Previously cleared a p-tau217 test for diagnostic use; regulatory stance influences adoption.
Importance 30.0 Sentiment 5.0
priv
Fujirebio
Manufactures the FDA-cleared Lumipulse G pTau217 test; potential commercial beneficiary.
Importance 30.0 Sentiment 25.0
per
Jessica Langbaum
Discouraged current use of test in asymptomatic individuals; from Banner Alzheimer s Institute.
Importance 30.0 Sentiment 0.0
per
Richard A. Isaacson
Cautioned against using p-tau217 test in isolation; from Institute for Neurodegenerative Diseases.
Importance 30.0 Sentiment 0.0
priv
Banner Alzheimer s Institute
Affiliation of Jessica Langbaum; provided expert opinion.
Importance 20.0 Sentiment 0.0
priv
Institute for Neurodegenerative Diseases
Affiliation of Richard A. Isaacson; provided expert commentary.
Importance 20.0 Sentiment 0.0
per
Laura Nisenbaum
Stated blood tests are not a diagnosis; from Alzheimer s Drug Discovery Foundation.
Importance 20.0 Sentiment 0.0
ngo
Alzheimer s Drug Discovery Foundation
Funds Alzheimer's research; provided expert opinion.
Importance 20.0 Sentiment 0.0
per
Manisha Parulekar
Commented on the test's promise and risks; not directly involved in the study.
Importance 15.0 Sentiment 0.0
subs
Warner Bros. Discovery — CNN
Reported on the study; not an actor in the event.
Importance 10.0 Sentiment 0.0
+ 1 more entities View on Dashboard
Relationships
Reisa Sperling related ↔ Alzheimer s Association
Alzheimer s Association related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.